This post is one in a series in which more than 60 newsletter advisors share their Top Stock Picks for 2011. This special report is courtesy of TheStockAdvisors.com.

"Our top stock pick for 2011 is a very speculative play, based on our conviction that at some point during the year, gold bullion will experience a strong run-up in price, perhaps reminiscent to the peak that occurred in January 1980," says Alan Newman.

The editor of CrossCurrents explains, "The Global X Explorers ETF (GLDX) is a brand new addition and began trading this past November.

"The market's seasonal effects have been nothing short of phenomena; for six decades, if you invested money only during the months from November through April, you made lots of money," says Alan Newman.

In a review of "seasonal market timing", the editor of CrossCurrent explains, "If you instead invested money only during the months from May through October, you lost money. You heard that right. Over a period measuring six decades, you would have lost money.

"The statistics represent far and away the most significant dichotomy ever seen in stock investing. If you invested $10,000 in the Dow from November through April, you'd have almost $517,000 now, an annualized rte of gain of 14.1%.

This post is part of a special report, Top Picks for 2010, the 27th annual survey in which TheStockAdvisors.com asks the nation's leading advisors for their single favorite stock for the new year. See all 80 stocks listed here.

"Mindray Medical International Limited (MR), a China-based medical devices firm, is our top investment idea for the coming year," says Alan Newman.

In his CrossCurrents newsletter, he notes, "The company is headquartered in Shenzhen, China, and is one of many Chinese companies now specializing in the development, manufacture and marketing of medical devices worldwide.

This post is part of a special annual report -- Top Stock Picks '09 -- in which TheStockAdvisors.com asked 75 leading newsletter advisors to select their favorite investment for the new year.

"We're not bullish on stocks until we see an improving economy; but if I had to choose a top pick for 2009, I have no problems choosing Pfizer (NYSE: PFE)," says Alan Newman in CrossCurrents.

"Given a lousy environment for stocks in the last half of 2008 and what appears to be the same going forward for the year ahead, the only logical course is to choose a company that pays a generous dividend.

"That will reward us for whatever patience will be required for our investment holding period. Thus, Pfizer, with its hefty 7.5% yield, makes good sense.

"In a bear market such as now, there are always minuses to consider. Pfizer has recently announced that, for the first time in 40 years, they are not raising their dividend.

"As well, Lipitor is the company's most successful product and it will lose patent protection just a couple of years down the road. Furthermore, there does not seem to be any blockbusters in the pipeline to replace Lipitor's $13 billion in sales.